Perhexiline maleate
产品说明书
 |
同义名 : | 哌克昔林 马来酸盐 ;Perhexiline (maleate) |
| CAS号 : | 6724-53-4 | |
| 货号 : | A645812 | |
| 分子式 : | C23H39NO4 | |
| 纯度 : | 99%+ | |
| 分子量 : | 393.56 | |
| MDL号 : | MFCD00057329 | |
| 存储条件： |
Pure form Inert atmosphere, 2-8°C In solvent -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 3 mg/mL(7.62 mM)，配合低频超声，并水浴加热至45℃助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO 无水乙醇: 25 mg/mL(63.52 mM)，配合低频超声，并水浴加热至45℃助溶，注意：无水乙醇开封后，易挥发，也会吸收空气中的水分，导致溶解能力下降，请避免使用开封较久的乙醇 |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Perhexiline maleate, an orally active inhibitor of CPT1 and CPT2, curtails fatty acid metabolism and induces mitochondrial dysfunction and apoptosis in hepatic cells. It can cross the blood-brain barrier (BBB) and exhibits anti-tumor properties. Perhexiline maleate is researched for its potential therapeutic applications in cancer and cardiovascular diseases such as angina[1].[2].[5]. | ||
| 临床研究 | |||||
|---|---|---|---|---|---|
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT02431221 | Hypertrophic Cardiomyopathy | Phase 3 | Withdrawn(Lack of efficacy in ... 展开 >>a preceding study.) 收起 << | - | - |
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
2.54mL 0.51mL 0.25mL |
12.70mL 2.54mL 1.27mL |
25.41mL 5.08mL 2.54mL |
| 参考文献 |
|---|
|
[1]E. Marc Jolicoeur, et al. 27 - Refractory Angina. Chronic Coronary Artery Disease, 2018, 412-431. |